Lee Brown with Third Bridge argues that demanding expectations are built into Eli Lilly's (LLY) stock following a "monstrous" 2Q earnings report. Mounjaro and Zepbound no longer on short supply helps the outlook, but Lee looks into other headwinds facing the pharmaceutical company, including the ILA Union's port worker strike.